TARGETED ALPHA PARTICLE THERAPY FOR NEUROENDOCRINE TUMOURS:
THE NEXT GENERATION OF PRRT
Authors of this article are:
Grossman A, Navalkissoor S.
A summary of the article is shown below:
Neuroendocrine tumours (NETs) are being seen increasingly frequently, but to date only complete surgical resection is curative. However, among the various therapeutic options, peptide receptor radionuclide therapy (PRRT), linking a radioactive moiety to an octreotide derivative, has been shown to be highly efficacious and a well-tolerated therapy, improving progression-free survival and probably overall survival. Nevertheless, the current radionuclides in use are β-particle emitters with non-optimal radiobiological properties. A new generation of α-particle emitting radionuclides is being developed, with advantages in terms of very high energy and a short path length, which should theoretically show higher efficacy. We survey the current developments in this field, emphasising the exciting potential of this novel form of therapy for NETs.
Check out the article’s website on Pubmed for more information:
This article is a good source of information and a good way to become familiar with topics such as:
Categories: Science News